WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals
World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: FEBRUARY ISSUE PUBLISHED

    FEBRUARY 2024 Issue has been successfully launched on 1 FEBRUARY 2024.

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR February 2023 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

HYPOKINETIC RIGID SYNDROME, IDIOPATHIC PARKINSON’S: A SMALL ACT OF CARING TO TURN A POTENTIAL LIFE

*Tanima Debnath Sarkar, John Anbumani Ganesan and P. Senthil Elango

ABSTRACT

In Parkinson's disease (PD), the degeneration of the substantia nigra disrupts the nigrostriatal pathway, leading toa reduction in striatal dopamine levels and the emergence of PD symptoms. While dopamine itself faceschallenges in crossing the blood-brain barrier, its precursor, levodopa, is capable of doing so. Levodopa undergoesabsorption in the small bowel and is swiftly broken down by aromatic-L-amino-acid decarboxylase (AADC) andcatechol-O-methyltransferase (COMT). Given that gastric AADC and COMT contribute to the degradation oflevodopa, the drug is administered alongside inhibitors of AADC (such as carbidopa or benserazide).Additionally, inhibitors of COMT are anticipated to see clinical use. The specific location of the decarboxylationof exogenous levodopa to dopamine in the brain remains unknown, but a significant portion of striatal AADC issituated in the nerve terminals of nigrostriatal dopaminergic pathways. Dopamine, synthesized and stored a newterminals and subsequently released which stimulates postsynaptic dopamine receptors, mediating theantiparkinsonian effects of levodopa. Dopamine agonists, in contrast, act directly on postsynaptic dopaminereceptors, eliminating the need for metabolic conversion, storage, and release. Parkinson disease protein7(PARK7) or Protein deglycase (DJ-1) is a gene responsible for hereditary recessive Parkinson's disease (PD). Thepotential inhibition of monoamine oxidase B (MAO-B) getting from chalcone in human body by adenosine A2Areceptor (AA2AR) antagonists has sparked interest in developing drugs that target both receptors. This dual-targetapproach holds promise for not only improving symptomatic relief but also potentially slowing the progression ofParkinson's disease (PD) by safeguarding against additional neurodegeneration.

[Full Text Article] [Download Certificate]